Shanghai Pharmaceuticals Holding(02607) plans to invest 300 million yuan to participate in the establishment of Shanghai Biopharmaceutical Phase II Fund.

Shanghai Pharmaceuticals Holding (02607) announced that on July 17, 2026, the board of directors approved the company's participation in the establishment of the Shanghai Biopharmaceutical Phase II Fund. The company (as a limited partner), Shanghai Pharma Group (as a limited partner), CICC Capital (as a limited partner), Pudong Leading District Fund (as a limited partner), Pudong Life Sciences (as a limited partner), Guotai Junan Innovation Fund (as a limited partner), Beijing Qianyu (as a limited partner), JUNSHI BIO (as a limited partner), Shenshi Capital (as a general partner) and Shenshi Management Consult (as a general partner) plan to subscribe to the Shanghai Biopharmaceutical Phase II Fund with capital contributions of 300 million, 300 million, 450 million, 100 million, 100 million, 100 million, 80 million, 50 million, 19 million and 1 million respectively. The company's participation in the establishment of the Shanghai Biopharmaceutical Phase II Fund is of strategic significance for the development of the biopharmaceutical industry in Shanghai and the company's future high-quality development. The Shanghai Biopharmaceutical Phase II Fund will serve as an important tool to drive the construction of the company's innovation system and achieve the strategic goal of "Great BD", aiming to build an internal closed-loop ecosystem covering multiple dimensions such as "discovery, transformation, and landing". This will provide the company with a high-quality early project reserve pool, effectively control investment risks, achieve precise supplementation of the R&D pipeline, and systematically enhance clinical translational efficiency.